- Home
- BBT vs TARS Comparison
BBT vs TARS Comparison
Compare BBT & TARS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | BBT | TARS |
|---|---|---|
| Founded | 1846 | 2016 |
| Country | United States | United States |
| Employees | 2050 | N/A |
| Industry | Banks | Medicinal Chemicals and Botanical Products |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.7B | 2.7B |
| IPO Year | N/A | 2020 |
Fundamental Metrics
Financial Performance| Metric | BBT | TARS |
|---|---|---|
| Price | $27.69 | $62.39 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 4 | 6 |
| Target Price | $33.25 | ★ $89.00 |
| AVG Volume (30 Days) | ★ 685.4K | 656.3K |
| Earning Date | 04-29-2026 | 05-06-2026 |
| Dividend Yield | ★ 4.12% | N/A |
| EPS Growth | N/A | ★ 48.21 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $451,360,000.00 |
| Revenue This Year | $77.88 | $56.43 |
| Revenue Next Year | $4.31 | $30.19 |
| P/E Ratio | $29.98 | ★ N/A |
| Revenue Growth | N/A | ★ 146.71 |
| 52 Week Low | $22.81 | $38.51 |
| 52 Week High | $32.83 | $85.25 |
Technical Indicators
Market Signals| Indicator | BBT | TARS |
|---|---|---|
| Relative Strength Index (RSI) | 31.18 | 45.30 |
| Support Level | $23.04 | $61.24 |
| Resistance Level | $28.04 | $67.24 |
| Average True Range (ATR) | 0.65 | 3.68 |
| MACD | -0.22 | 0.26 |
| Stochastic Oscillator | 4.71 | 54.14 |
Price Performance
Historical ComparisonAbout BBT Beacon Financial Corporation
Beacon Financial Corp operates as a multi-bank holding company. It offers commercial, business, and retail banking services, including a full complement of cash management products, online banking services, and consumer and residential loans.
About TARS Tarsus Pharmaceuticals Inc.
Tarsus Pharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the development and commercialization of therapeutics, starting with eye care. The company is focused on the development and commercialization of first-in-class therapeutic candidates to provide treatment for ophthalmic conditions. The company's candidate XDEMVY is a novel investigational eye drop to treat blepharitis caused by the infestation of Demodex mites, referred to as Demodex blepharitis. TP-04 for the potential treatment of ocular rosacea and TP-05 for potential Lyme disease prophylaxis and community malaria reduction.